Toronto

Dr. Scott Berry is a medical oncologist, Professor and Head of the Queen’s University Department of Oncology.  He is the Executive Director of the Queen’s Global Oncology Program and the Medical Director at the Cancer Centre of Southeastern Ontario at the Kingston Health Sciences Centre.  Dr. Berry’s clinical specialty is gastrointestinal cancer.  He is actively involved in clinical research and Co-Chair of the Gastrointestinal Disease Site Group of the Cancer Cancer Ontario Program in Evidence Based Care. Dr. Berry is a medical educator who has previously served as Chair of the Royal College of Physicians and Surgeons of Canada Specialty Committee for Medical Oncology.  He is one of the co-founders of OncologyEducation.com.  His other academic interest is the bioethical issues surrounding the care of people with cancer, in particular the ethical issues related to equitable access to cancer medications. He is a former member and ethics advisor to the pan-Canadian Oncology Drug Review Expert Review Committee and has served on the ASCO Ethics Committee.

Dr. Juergens received her medical degree from Georgetown University in Washington, D.C. She was an intern and resident in the Osler Internal Medicine Training Program at The Johns Hopkins Medical Institute. She completed a fellowship in medical oncology with a focus on upper aerodigestive malignancies as well at Johns Hopkins. Additionally, she completed her Ph.D. in Clinical Investigation at The Johns Hopkins Bloomberg School of Public Health. She was on the faculty at Johns Hopkins from 2007-2010 until she joined the faculty at McMaster University in 2011.
Dr. Juergens’ clinical expertise is in lung and esophageal cancer. She chairs the Lung Disease Site Team at the Juravinski Cancer Centre in Hamilton, Ontario. She is also a patient advocate and serves as the Medical Advisory Committee Chair for Lung Cancer Canada. She is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre. She is a member of the Escarpment Cancer Research Institute. Her areas of research expertise involve improving therapeutics and diagnostics in cancer.
Her research focus has been in developmental therapeutics with a concentration on Phase I and II clinical trials. She is the chair of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee. She is a member of the Cancer Research Institute’s Scientific Leadership Committee. She has published her work in prominent journals including such as the Journal of Clinical Oncology, The New England Journal of Medicine and Cancer Discovery. She has been a principal investigator on numerous clinical trials assessing treatments in lung cancer as well as esophagogastric cancer. She is a highly sought teacher in the field of immunotherapy and has been an invited speaker across the world.